Table 1.
Characteristics of populations and interventions in the included systematic reviews/meta-analyses on vitamin D and concomitant calcium supplementation compared to placebo/control
| Characteristics of populations and interventions | No. (%) or range |
|---|---|
| Mean age, y | 62-85.2 |
| Sex | |
| • Men and women | 9 (69) |
| • Women only | 2 (15) |
| • Not reported | 2 (15) |
| Residency status | |
| • Community-dwelling only | 3 (23) |
| • Institutionalized only | 0 (0) |
| • Both | 8 (62) |
| • Not reported | 2 (15) |
| Mean serum 25(OH)D concentration at baseline, nmol/L | 11.9-84 |
| • Reported | 5 (38) |
| • Not reported | 8 (62) |
| Mean serum 25(OH)D concentration at follow-up, nmol/L | 15.0-112 |
| • Reporteda | 1 (8) |
| • Not reported | 12 (92) |
| Vitamin D dose frequency | |
| • Daily, IU/d | 400-1600 |
| • Once, IU | 300 000 |
| Calcium dose, mg/d | 500-1200 |
| • Daily | |
| Vitamin D route of administration | |
| • Oral supplementation only | 1 (8) |
| • Oral and parenteral supplementation | 4 (31) |
| • Administration mode not mentioned | 8 (62) |
| Individual trial duration | |
| • SR/MA including ≥ 1 trial < 12 mo | 0 (0) |
| • SR/MA including all trials ≥ 12 mo | 9 (69) |
| • Not reported | 4 (31) |
| Fracture siteb | |
| • Hip | 12 |
| • Total/Any/Other | 11 |
| • Vertebral | 6 |
| • Nonvertebral | 5 |
| SR/MAs with trials on individuals at high risk of fracturec | 9 |
Abbreviations: 25(OH)D, 25-hydroxyvitamin D; IU, international units; SR/MA, systematic review and meta-analysis.
a Yao et al (30) reported change rather than follow up 25-hydroxyvitamin D concentration.
b Some MAs may include more than one fracture site.
c Previous fracture or osteopenia/osteoporosis.